MedTrace Logo

Sea Buckthorn Aqueous Infusion Impact

NCT07313423 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-02

No results posted yet for this study

Summary

* A total of 60 overweight women (BMI 25-29.9 kg/m²), aged 18-50years, will be enrolled and randomized equally into intervention and control groups. The intervention group will consume a 5 g freshly prepared seabuckthorn aqueous infusion daily for 12 weeks, while controls maintain usual habits without supplementation.
* The seabuckthorn aqueous infusion will be prepared by using 250mL of potable boiled water and then cooled to a lukewarm temperature (around 40-45°C). At this point, 5 g of seabuckthorn powder will be added, stirred thoroughly until fully dispersed, and consumed immediately. The infusion will be freshly prepared once daily and administered in the morning after breakfast.

Measurements will be conducted using the InBody 270, a validated bioelectrical impedance analyzer employed in this study to obtain accurate assessments of body weight, body mass index (BMI), waist-hip ratio, and visceral fat levels. The device offers segmental analysis and visceral fat estimation through non-invasive, standardized procedures, ensuring consistency and reliability in longitudinal tracking.

Conditions

  • Body Compostition

Interventions

DIETARY_SUPPLEMENT

Sea buckthorn aqueous infusion

Sea buckthorn aqueous infusion prepared by using 5g powder in 250 ml water.

Sponsors & Collaborators

  • University of Veterinary and Animal Sciences, Lahore - Pakistan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-03-30
Completion
2026-04-15

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313423 on ClinicalTrials.gov